Company Overview and News

 
TransCanada's (TRP) CEO Russ Girling on Q4 2017 Results - Earnings Call Transcript

2018-02-16 seekingalpha
Good day, ladies and gentlemen. Welcome to the TransCanada Corporation 2017 Fourth Quarter Results Conference Call. I would now like to turn the meeting over to Mr. David Moneta, Vice President, Investor Relations. Please go ahead, Mr. Moneta.
Upvote Downvote

 
What’s Impacting TransCanada’s Earnings?

2018-01-11 editors.aws.marketrealist
TransCanada (TRP) operates through five segments. Its Energy business includes power generation and natural gas storage. TransCanada sold its U.S. Northeast power business in 2Q17, which impacted the company’s earnings in the third quarter of 2017.
Upvote Downvote

 
TransCanada (TRP) to Proceed With $6 Billion PRGT Project

2018-01-09 zacks
After a careful and comprehensive review of its Prince Rupert Gas Transmission Project (PRGT), TransCanada Corporation (TRP - Free Report) has decided to advance with the $6-billion natural gas pipeline expansion plan.  After a few setbacks, TransCanada finally received approval from the B.C. Environmental Assessment Office for the pipeline’s expansion on Dec 20, 2017.
Upvote Downvote

 
TransCanada (TRP) Leach Xpress Pipeline Becomes Operational

2018-01-05 zacks
TransCanada Corporation (TRP - Free Report) recently announced that its natural gas pipeline system Leach XPress was placed in-service on Jan 1, 2018. The pipeline is 160 miles long and has the capacity to transport 1.5 billion cubic feet/day (Bcf/d) of gas.
Upvote Downvote

1
TransCanada's Sleepy Cash Flow Cow

2018-01-03 seekingalpha
Power plants and unregulated storage facilities may be a sleepy business, but they do generate a lot of cash flow.
Upvote Downvote

 
Leach XPress Project Placed into Service; Mountaineer XPress, Gulf XPress Receive FERC Certificates

2018-01-02 marketwired
HOUSTON, TEXAS--(Marketwired - Jan. 2, 2018) - News Release - TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada) today announced its Leach XPress (LXP) project was placed in-service on January 1, 2018, and that the Federal Energy Regulatory Commission (FERC) has issued a certificate of public convenience and necessity for its Mountaineer XPress (MXP) and Gulf XPress (GXP) projects on December 29, 2017.
Upvote Downvote

 
TransCanada's History And Growth Support Continued Dividend Growth

2017-12-26 seekingalpha
TransCanada has recently completed a $13 billion acquisition of Columbia Pipeline Partners and accomplished $0.25 billion in synergies increasing its cash flow here.
Upvote Downvote

 
No Longer A Keystone For TransCanada

2017-12-07 seekingalpha
Last month, the Nebraska Public Service Commission approved the northern leg of the Keystone XL pipeline, removing the last major regulatory hurdle after the U.S. State Department signed off on the controversial project's border crossing. However, investors who still regard this project as the primary upside driver for TransCanada Corp. (NYSE:TRP) should curb their enthusiasm.
Upvote Downvote

 
TransCanada Engages Nebraska Landowners On New Keystone XL Route

2017-11-28 rigzone
Calgary, Alberta/TORONTO, Nov 28 (Reuters) - TransCanada Corp has started engaging landowners on a new route for its Keystone XL pipeline approved by the state of Nebraska, the company said on Tuesday, exploring the costlier path as it mulls a final decision on the expansion project mooted nearly a decade ago.
Upvote Downvote

 
TransCanada eyeing new names that lose "Canada"

2017-11-08 worldoil
CALGARY and NEW YORK (Bloomberg) -- TransCanada Corp., which diversified heavily into the U.S. with its $10.2-billion Columbia Pipeline Group Inc. acquisition last year, is seeking trademarks on new company names that would excise its home country.
Upvote Downvote

 
TransCanada Eyes New Names, Without the ‘Canada’ - Bloomberg

2017-11-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
TransCanada selling Ontario solar power holdings in move against renewable energy trend

2017-10-25 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Upvote Downvote

 
TransCanada selling Ontario solar portfolio in further move from renewables

2017-10-25 ctvnews.ca
CALGARY -- TransCanada Corp. is offloading its only solar power holdings in a $540-million deal as it moves against the industry trend of investing more in renewables.
Upvote Downvote

 
UPDATE 1-TransCanada to sell solar assets, focus on C$24 bln capital program

2017-10-25 reuters
(Reuters) - Canadian pipeline operator TransCanada Corp (TRP.TO) has agreed to sell its solar energy portfolio for C$540 million ($426 million) to focus on its C$24 billion worth of other core projects, including its recently purchased Columbia natural gas network, the company said on Wednesday.
Upvote Downvote

 
Columbia Pipeline Group ER

2017-10-04 sec.gov
March 6, 2015 Stephen P. Smith President Columbia Pipeline Group, Inc. 5151 San Felipe Street, Suite 2500 Houston, Texas 77056 Re: Columbia Pipeline Group, Inc. Registration Statement on Form 10 Filed February 6, 2015 File No. 001-36838 Dear Mr. Smith: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 198280109